

Performance in initiating Q3 & Q4 01/01/2021-14/05/2021

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
180103	20/EE/0101	281712	RECOVERY	Yes	25/03/2020	1	7	8	17/03/2020	17/03/2020	14/03/2020	17/03/2020	18/03/2020	Please Select...	25/03/2020			Please Select...
180105	18/LO/0660	237150	REMAP-CAP	No		16			14/04/2020	18/04/2020	23/07/2018	13/05/2020	04/05/2020	Please Select...	16/06/2020	G - No patients consented	no patients met the criteria	Neither
180217	20/SC/0418	282222	A randomised, double-blind, placebo controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2	No		17			24/11/2020	17/12/2020	13/11/2020	22/12/2020	03/01/2021	Please Select...	08/01/2021	J - Other	There has been a decline in the number of patients being admitted with COVID 19	Sponsor